First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) TÂ Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study Post author:andrewkaretas Post published:June 1, 2021 Post category:CD19/Scientific Publications Continue ReadingFirst-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) TÂ Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study
American Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study Post author:andrewkaretas Post published:May 1, 2020 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study
American Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies Post author:andrewkaretas Post published:December 1, 2018 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies